The global cell-based assay market was valued $ 11,744 million in 2020 and expected to reach $26,348 million by 2030, with a CAGR of 8.2% from 2021 to 2030.
Cell-based assays are in-vitro assays that are used to examine a variety of cellular characteristics, such as cytotoxicity and cell signaling activation. Cell-based assays and analyses are viable experimental instruments in life sciences research and bio production. The method is based on cell culture procedures, in which living cells are produced in in-vitro and used as model systems for evaluating the biochemistry and physiology of both, healthy and sick cells.
The cell-based assays market is expected to rise in revenue due to technological improvements and widespread use of assays in numerous medicinal applications. Furthermore, a number of major firms are focused on tactics to develop their respective product lines and portfolios, as well as to maintain their market position. Cell-based assays are analytical methods used to investigate a cellular function mechanism or process. Consumables such as reagents, test kits, and microplates, as well as instruments, services, and software, are available from companies creating cell-based assays. Reagents, cell lines, microplates, microplates, assay kits, probes and labels, and other items are included in this report. The high cost of instruments is a major restraint on the global market for cell-based assays. Due to low adaptability, the high cost of the instruments will diminish the return on investment (ROI). Biotek, for example, created HCA (high content analysis) devices, which are costly and only available to industrial end-users or core labs with appropriate capital budgets. The high demand for cell-based tests in drug development and discovery drives the revenue growth of the market. Furthermore, technological advancements in cell-based assays, expanding usage of 3D-based cell assays, and the growing necessity for generating biologically relevant replacements for drug discovery are all contributing to market expansion.
The industry's participants are modifying their long- and short-term growth strategies to capitalize on opportunities in the research market by introducing innovative goods to combat the pandemic. For both, researchers and laboratories, the rise in need for COVID-19 research has provided a wide scope for cell-based 45 tests in viral infection research, vaccine development, and overall drug discovery. A variety of COVID-19 vaccines or antiviral medications have been approved or are in development, and patients are now being treated symptomatically. The functional efficiency of the antibodies produced to neutralize the target virus is assessed for both vaccinations and treatments Cell-based assays are used to reduce the time and boost the throughput of these experiments
The cell-based assay market is segmented on the basis of product, application, end user, and geography. On the basis of product, it is categorized into consumable, instrument, service, and software. The consumable segment includes reagents, microplates, probes & labels, assay kits, cell lines, and others. Assay kits are further sub-divided into reporter gene assays, cell growth assays, second messenger assays, cell death assays, and others. Likewise, the cell lines are divided into immortalized cell lines, primary cell lines, and stem cell lines. On the basis of application, the market is divided into drug discovery; basic research; absorption, distribution, metabolism, & excretion (ADME) studies; predictive toxicology; and others.
On the basis of end user, it is categorized into pharmaceutical & biotechnology companies, academic & government research institutes, contract research organizations, and others. On the basis of region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The key players operating in the global cell-based assay market are Becton, Dickinson and Company, Danaher Corporation, Thermo Fisher Scientific, Inc., General Electric Company, Merck KGaA, Perkinelmer, Inc., Bio-Rad Laboratories, Inc., Lonza Group Ltd., Cell Signaling Technology, Inc., and Promega Corporation.
The other prominent players in the value chain include Macrogen, Inc., New England Biolabs, Inc., Cisbio Bioassays, Cell Biolabs, Inc., and DiscoverX Corporation.
Cell-based assays are in-vitro assays that are used to examine a variety of cellular characteristics, such as cytotoxicity and cell signaling activation. Cell-based assays and analyses are viable experimental instruments in life sciences research and bio production. The method is based on cell culture procedures, in which living cells are produced in in-vitro and used as model systems for evaluating the biochemistry and physiology of both, healthy and sick cells.
The cell-based assays market is expected to rise in revenue due to technological improvements and widespread use of assays in numerous medicinal applications. Furthermore, a number of major firms are focused on tactics to develop their respective product lines and portfolios, as well as to maintain their market position. Cell-based assays are analytical methods used to investigate a cellular function mechanism or process. Consumables such as reagents, test kits, and microplates, as well as instruments, services, and software, are available from companies creating cell-based assays. Reagents, cell lines, microplates, microplates, assay kits, probes and labels, and other items are included in this report. The high cost of instruments is a major restraint on the global market for cell-based assays. Due to low adaptability, the high cost of the instruments will diminish the return on investment (ROI). Biotek, for example, created HCA (high content analysis) devices, which are costly and only available to industrial end-users or core labs with appropriate capital budgets. The high demand for cell-based tests in drug development and discovery drives the revenue growth of the market. Furthermore, technological advancements in cell-based assays, expanding usage of 3D-based cell assays, and the growing necessity for generating biologically relevant replacements for drug discovery are all contributing to market expansion.
The industry's participants are modifying their long- and short-term growth strategies to capitalize on opportunities in the research market by introducing innovative goods to combat the pandemic. For both, researchers and laboratories, the rise in need for COVID-19 research has provided a wide scope for cell-based 45 tests in viral infection research, vaccine development, and overall drug discovery. A variety of COVID-19 vaccines or antiviral medications have been approved or are in development, and patients are now being treated symptomatically. The functional efficiency of the antibodies produced to neutralize the target virus is assessed for both vaccinations and treatments Cell-based assays are used to reduce the time and boost the throughput of these experiments
The cell-based assay market is segmented on the basis of product, application, end user, and geography. On the basis of product, it is categorized into consumable, instrument, service, and software. The consumable segment includes reagents, microplates, probes & labels, assay kits, cell lines, and others. Assay kits are further sub-divided into reporter gene assays, cell growth assays, second messenger assays, cell death assays, and others. Likewise, the cell lines are divided into immortalized cell lines, primary cell lines, and stem cell lines. On the basis of application, the market is divided into drug discovery; basic research; absorption, distribution, metabolism, & excretion (ADME) studies; predictive toxicology; and others.
On the basis of end user, it is categorized into pharmaceutical & biotechnology companies, academic & government research institutes, contract research organizations, and others. On the basis of region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The key players operating in the global cell-based assay market are Becton, Dickinson and Company, Danaher Corporation, Thermo Fisher Scientific, Inc., General Electric Company, Merck KGaA, Perkinelmer, Inc., Bio-Rad Laboratories, Inc., Lonza Group Ltd., Cell Signaling Technology, Inc., and Promega Corporation.
The other prominent players in the value chain include Macrogen, Inc., New England Biolabs, Inc., Cisbio Bioassays, Cell Biolabs, Inc., and DiscoverX Corporation.
KEY BENEFITS FOR STAKEHOLDERS
- The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets
- It offers a quantitative analysis from 2020 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities
- A comprehensive analysis of four regions is provided to determine the existing opportunities
- The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market
KEY MARKET SEGMENTS
By Product
- Consumable
- Reagents
- Microplates
- Probes & Labels
- Assay Kits
- Reporter Gene Assays
- Cell Growth Assays
- Second Messenger Assays
- Cell Death Assays
- Others
- Cell Lines
- Immortalized Cell Lines
- Primary Cell Lines
- Stem Cell Lines
- Other Cell Line
- Other Cell Line
- Instrument
- Service
- Software
By End User
- Pharmaceutical & Biotechnology Companies
- Academic & Government Research Institutes
- Contract Research Organizations
- Others
By Application
- Drug Discovery
- Basic Research
- ADME Studies
- Predictive Toxicology
- Others
By Region
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Taiwan
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
Chapter 1: Introduction
Chapter 2: Executive Summary
Chapter 3: Market Landscape
Chapter 4: Cell Based Assay Market, by Product
Chapter 5: Cell Based Assay Market, by Application
Chapter 6: Cell Based Assay Market, by End-user
Chapter 7: Cell Based Assay Market, by Region
Chapter 8: Cell Based Assay Market, by Region
Chapter 9: Company Profiles
List of Tables
List of Figures
Executive Summary
According to a new report titled, Cell-Based Assays Market by Product, Application, and End User: Global Opportunity Investigation and Industry Forecast, 2021-2030” the global cell-based assay market size was worth $12 billion in 2020 and is expected to reach $26 billion by 2030, with a CAGR of 8.2% from 2022 to 2030.Cell-based assay can be referred as any experiment that uses a live cell. A variety of cell-based assays can be used to measure cell toxicity, proliferation, motility, as well as the generation of a specific cellular product and cellular morphology. Cell-based assays are a better depiction of the real-life model because live cells are used in the experiment. Cell-based assays have evolved into a flexible tool in healthcare R&D, particularly in investigations aimed at understanding specific cell functions, such as antibody function or therapeutic efficacy on a set of cells. Cell-based tests are essential in the drug development process. In vitro biochemical assays have various advantages over cell-based techniques. In contrast to biochemical experiments, they provide consistent tissue-specific responses in a physiologically relevant milieu. Also, not every target for biochemical measurement can be prepared or purified, which is a major factor restricting biochemical assay uses.
The major factors that drive global cell-based assay market include pharmaceutical and biotechnology companies, as well as contract research organizations (CROs), which are replacing biochemical tests with cell-based assays in their drug discovery led identification and optimization procedures. Furthermore, traditional toxicity and drug safety assessment approaches (which involve animal testing) are costly, time-consuming, and low-throughput. In this sense, contemporary cell-based assays combine the benefits of cell cultures and animal models to allow researchers to uncover problems with lead compounds early in the drug discovery and development process, assuring higher efficiency. Cell-based assays' physiological relevance, as well as their capacity to provide efficient, cost-effective, and expedited drug development solutions, have spurred their increased popularity among end users. Various public and corporate entities have increased their R&D funding to discover better and safer pharmaceuticals. Furthermore, advances in cell-based assay technology have allowed researchers to use this method for drug discovery and toxicology studies. Another major factor attributing the growth of the market is the rise in prevalence of lifestyle diseases such as arthritis, diabetes, epilepsy, cancer, cardiovascular diseases, and others, which still have large unmet needs and have led to continuous investments in R&D. This market is also being driven by increase in the usage of cell-based assay techniques for high throughput screening methods, such as toxicity studies, drug screening, in vitro testing, and others.
The World Health Organization (WHO) on January 30, 2020, declared COVID-19 outbreak a public health emergency of international concern. COVID-19 has affected around 210 countries across the globe. Due to the COVID-19 pandemic, governments across the globe announced country-wide lockdowns as well as social distancing measures to prevent collapse of the healthcare system. The overall impact of COVID-19 on the global cell-based assay market was positive owing to significant increment in chronic diseases, surge in funding in R&D sectors, surge in establishments of biotechnology and pharmaceutical manufacturing units, and rise in lifestyle disorders.
The cell-based assay market is segmented on the basis of product, application, end user, and region. On the basis of product, it is categorized into consumable, instrument, service, and software. The consumable segment includes, reagents, microplates, probes & labels, assay kits, cell lines, and others. Assay kits are further sub-divided into reporter gene assays, cell growth assays, second messenger assays, cell death assays, and others. Likewise, the cell lines are divided into immortalized cell lines, primary cell lines, and stem cell lines. By application, the market is divided into drug discovery; basic research; absorption, distribution, metabolism, & excretion (ADME) studies; predictive toxicology; and others. On the basis of end user, it is categorized into pharmaceutical & biotechnology companies, academic & government research institutes, contract research organizations, and others. On the basis of region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
On the basis of product, the cell-based assay market is segmented into consumables, instruments & software, and services. Consumables dominated the market due to the repeated purchase of consumables by pharmaceutical and biopharmaceutical companies.
On the basis of application, the cell-based assay market is categorized into drug discovery, basic research, and other applications. The drug discovery application segment dominated the market, which is attributed to increase in funding in the R&D sector, technological advancements, introduction of new drugs, surge in lifestyle disorders, the growing number of CROs providing drug discovery services, and surge in manufacturing units of biotechnology and pharmaceuticals.
On the basis of end users, the cell-based assay market is segmented into pharmaceutical and biopharmaceutical companies, CROs, and academic and research institutes. Pharmaceutical & biotechnology companies dominated the market in 2019. The large share of this segment can be attributed to the exposure of technology, increase in R&D expenditure, the growing number of drug discovery projects, growing number of chronic and lifestyle disorders, and the adoption of strategic approaches such as collaborations to develop drug candidates.
In addition, North America accounted for the largest share of the cell-based assays market, followed by Europe. The large share of the North American regional segment can be attributed to the availability of funding’s in R&D sectors, surge in lifestyle disorders, rise drug discovery, and the rapid adoption of advanced technologies in the region.
Key Findings Of Study
- The study gives a top to bottom investigation of the cell-based assay market, with most recent things and future appraisals to explain the imminent investment pockets
- It gives a quantitative investigation from 2020 to 2030 to engage the accomplices to gain by prevailing market opportunities
- Wide investigation by product type and end user determines the various trends and prevailing opportunities in the different market
- Complete examination of all land regions is given, which assist with determining the main opportunities
- Key market players are profiled and their strategies are investigated totally to expect the relentless standpoint of the cell-based assay market
Companies Mentioned
- Becton, Dickinson and Company
- Danaher Corporation
- Thermo Fisher Scientific, Inc.
- General Electric Company
- Merck KGaA
- Perkinelmer, Inc.
- Bio-Rad Laboratories, Inc.
- Lonza Group Ltd.
- Cell Signaling Technology, Inc. and
- Promega Corporation.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 264 |
| Published | March 2022 |
| Forecast Period | 2020 - 2030 |
| Estimated Market Value ( USD | $ 11744 million |
| Forecasted Market Value ( USD | $ 26348 million |
| Compound Annual Growth Rate | 8.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
